The National Pancreas Foundation (NPF) provides hope for those suffering from pancreatitis and pancreatic cancer through funding cutting-edge research, advocating for new and better therapies, and providing support and education for patients, caregivers, and healthcare professionals.
The National Pancreas Foundation (NPF) provides hope for those suffering from pancreatitis and pancreatic cancer through funding cutting-edge research, advocating for new and better therapies, and providing support and education for patients, caregivers, and healthcare professionals.
To fulfill its mission, the NPF raises and manages a charitable foundation from which grants are made directly to researchers seeking to resolve the challenging medical problems of pancreatic diseases. The NPF is the only foundation dedicated to patients who are suffering from all forms of pancreas disease—pediatric pancreatitis, acute pancreatitis, chronic pancreatitis, and pancreatic cancer. A National Patient Registry is being developed for individuals suffering the isolating and debilitating conditions associated with pancreatic disease.
The NPF and its founding members and volunteers are committed to maximum efficiency, with the goal of directing as much revenue as possible to programs. To achieve this, NPF relies heavily on the invaluable donations of time, energy, and financial support of the many friends and interested parties who have been touched by the suffering of so many people.
With the help of the foundation’s Grant Review Council, the NPF makes grants to those whose proposals appear most likely to lead to scientific advancements in the field of pancreatic disease. Founded in 1997, the NPF has given over $2.5 million to fund 92 groundbreaking research projects.
The Foundation advocacy efforts have also been very effective, actively participating on the advisory council for the National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institute Gastrointestinal Steering Committee, and as Department of Defense Consumer Reviewers. Furthermore, the NPF has supported initiatives that have led to millions of dollars of additional research funding by the National Institutes of Health, the Department of Defense, and other institutions.
Addition of Concomitant TTFields Induces OS Benefit in Unresectable Pancreatic Cancer
December 4th 2024The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its primary end point of overall survival in unresectable, locally advanced pancreatic adenocarcinoma.